5th mRNA Process Development & CMC Summit

• Persistent virus reservoirs associated with dysfunctional anti-viral T cell responses is a root cause of Long COVID, a debilitating disease affecting >400 million people globally
• We have developed an mRNA-based immunotherapeutic targeting protective T cell antigens of SARS-CoV-2
• Treatment of Long COVID in mice resulted in reversal of T cell dysfunction, clearance of virus reservoirs, and amelioration of cognitive and behavioural deficits

Key questions include:

• How do you structure CDMO partnerships to balance speed, flexibility, and risk without overcomplicating your manufacturing network?
• What are the biggest misalignments between biopharma and CDMOs during scale-up – and how can they be avoided early?
• At what point should companies start designing for commercial-scale manufacturing, and how does that shape CDMO and supply chain decisions?